Limits...
mTOR pathway: A current, up-to-date mini-review (Review).

Zarogoulidis P, Lampaki S, Turner JF, Huang H, Kakolyris S, Syrigos K, Zarogoulidis K - Oncol Lett (2014)

Bottom Line: Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially identified as the cellular target of rapamycin.This kinase regulates cell growth, proliferation, motility and survival, as well as the gene transcription and protein synthesis that are activated in response to hormones, growth factors and nutrients.Results from preclinical studies have indicated that factors antagonizing the mTOR pathway exert an antitumor effect on lung cancer.

View Article: PubMed Central - PubMed

Affiliation: Pulmonary Department-Oncology Unit, G. Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki 57010, Greece.

ABSTRACT
Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation, motility and survival, as well as the gene transcription and protein synthesis that are activated in response to hormones, growth factors and nutrients. Results from preclinical studies have indicated that factors antagonizing the mTOR pathway exert an antitumor effect on lung cancer. Furthermore, primary clinical trials of mTOR inhibitors have demonstrated that the inhibitors may be effective against lung carcinoma. The present study explores the association between mTOR and lung carcinogenesis and describes the clinical trials of mTOR inhibitors.

No MeSH data available.


Related in: MedlinePlus

Activation of mammalian target of rapamycin occurs through a complex signaling cascade. mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214394&req=5

f1-ol-08-06-2367: Activation of mammalian target of rapamycin occurs through a complex signaling cascade. mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase.


mTOR pathway: A current, up-to-date mini-review (Review).

Zarogoulidis P, Lampaki S, Turner JF, Huang H, Kakolyris S, Syrigos K, Zarogoulidis K - Oncol Lett (2014)

Activation of mammalian target of rapamycin occurs through a complex signaling cascade. mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214394&req=5

f1-ol-08-06-2367: Activation of mammalian target of rapamycin occurs through a complex signaling cascade. mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase.
Bottom Line: Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially identified as the cellular target of rapamycin.This kinase regulates cell growth, proliferation, motility and survival, as well as the gene transcription and protein synthesis that are activated in response to hormones, growth factors and nutrients.Results from preclinical studies have indicated that factors antagonizing the mTOR pathway exert an antitumor effect on lung cancer.

View Article: PubMed Central - PubMed

Affiliation: Pulmonary Department-Oncology Unit, G. Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki 57010, Greece.

ABSTRACT
Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation, motility and survival, as well as the gene transcription and protein synthesis that are activated in response to hormones, growth factors and nutrients. Results from preclinical studies have indicated that factors antagonizing the mTOR pathway exert an antitumor effect on lung cancer. Furthermore, primary clinical trials of mTOR inhibitors have demonstrated that the inhibitors may be effective against lung carcinoma. The present study explores the association between mTOR and lung carcinogenesis and describes the clinical trials of mTOR inhibitors.

No MeSH data available.


Related in: MedlinePlus